US$ 21.04
fda bpc-157 not approved statement Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling fda bpc-157 not approved human
Description
Tuning immune suppression in systemic autoimmunity with self-derived peptides
It is studied in preclinical models of tissue and gastrointestinal repair

An Open-Label Phase II Study

However, its important to note that while MIC injections may support liver health, they should not be considered a treatment for liver disease
